Cough as a Clue: Tracheal Endocarcinoma Unveiled.

Autor:	Charii H; Department of Respiratory Diseases, Mohammed VI University Hospital, Oujda, MAR.; Department of Respiratory Diseases, Faculty of Medicine and Pharmacy, Mohammed First University, Oujda, MAR., Boudouh A; Department of Respiratory Diseases, Mohammed VI University Hospital, Oujda, MAR.; Department of Respiratory Diseases, Faculty of Medicine and Pharmacy, Mohammed First University, Oujda, MAR., Mezouari O; General Medicine, Faculty of Medicine and Pharmacy, Mohammed First University, Oujda, MAR., Moueqqit O; General Medicine, Faculty of Medicine and Pharmacy, Mohammed First University, Oujda, MAR., Kouismi H; Department of Respiratory Diseases, Mohammed VI University Hospital, Oujda, MAR.; Department of Respiratory Diseases, Faculty of Medicine and Pharmacy, Mohammed First University, Oujda, MAR.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2023 Jun 12; Vol. 15 (6), pp. e40335. Date of Electronic Publication: 2023 Jun 12 (Print Publication: 2023).
DOI:	10.7759/cureus.40335
Abstrakt:	Tracheal adenocarcinoma (TAC) is a rare malignancy often characterized by significant delays in diagnosis, often attributed to the non-specific nature of symptoms, leading to subsequent challenges in management. The prognosis remains poor, highlighting the need for early detection and multidisciplinary treatment strategies. Surgical resection is recommended for eligible patients, followed by postsurgical irradiation. However, further research is required to give a better perspective on therapeutic interventions and enhance patient outcomes. This paper reports the case of a 50-year-old male, who presented with dyspnea, hemoptysis, and cough. The computed tomography (CT) revealed an intratracheal tissue mass. The cytological examination and immunocytochemistry confirmed the diagnosis of primary adenocarcinoma in the trachea. The treatment involved silicone tracheobronchial Y-stent followed by adjuvant chemotherapy with carboplatin and paclitaxel, and radiotherapy (60 Gray) with good clinical improvement. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2023, Charii et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu